Publicaciones en colaboración con investigadores/as de University of Bologna (12)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

2022

  1. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

  2. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1185-1198

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

2020

  1. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial

    JAMA Oncology

  2. Epigenetic mechanisms in gastric cancer: Potential new therapeutic opportunities

    International Journal of Molecular Sciences, Vol. 21, Núm. 15, pp. 1-21

  3. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

  4. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

    Hepatology, Vol. 72, Núm. 1, pp. 198-212

2016

  1. Capsid-deficient alphaviruses generate propagative infectious microvesicles at the plasma membrane

    Cellular and Molecular Life Sciences, Vol. 73, Núm. 20, pp. 3897-3916

2011

  1. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation

    Hepatology, Vol. 54, Núm. 3, pp. 868-878